Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment.
Provencio M, Torrente M, Calvo V, Gutiérrez L, Pérez-Callejo D, Pérez-Barrios C, Barquín M, Royuela A, Rodriguez-Alfonso B, Sotelo M, Cruz-Bermúdez JL, Mendez M, Cruz-Bermúdez A, Romero A. Provencio M, et al. Oncotarget. 2017 Aug 7;8(36):60291-60298. doi: 10.18632/oncotarget.20016. eCollection 2017 Sep 1. Oncotarget. 2017. PMID: 28947971 Free PMC article.
Spotlight on the relevance of mtDNA in cancer.
Cruz-Bermúdez A, Vicente-Blanco RJ, Gonzalez-Vioque E, Provencio M, Fernández-Moreno MÁ, Garesse R. Cruz-Bermúdez A, et al. Clin Transl Oncol. 2017 Apr;19(4):409-418. doi: 10.1007/s12094-016-1561-6. Epub 2016 Oct 24. Clin Transl Oncol. 2017. PMID: 27778302 Review.
Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients.
Provencio M, Pérez-Callejo D, Torrente M, Martin P, Calvo V, Gutiérrez L, Franco F, Coronado MJ, Cruz-Bermúdez JL, Ruiz-Valdepeñas AM, Cruz-Bermúdez A, Sánchez-Beato M, Romero A, García-Grande A. Provencio M, et al. Oncotarget. 2017 Jul 31;8(35):59408-59416. doi: 10.18632/oncotarget.19722. eCollection 2017 Aug 29. Oncotarget. 2017. PMID: 28938646 Free PMC article.
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling.
Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Alfaro C, Sanchez JC, Franco F, Calvo V, Romero A, Martin-Acosta P, Salas C, Garcia JM, Provencio M. Cruz-Bermúdez A, et al. Free Radic Biol Med. 2019 Jan;130:163-173. doi: 10.1016/j.freeradbiomed.2018.10.450. Epub 2018 Nov 1. Free Radic Biol Med. 2019. PMID: 30391585 Free article.
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition.
Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Palacios-Zambrano S, Moreno-Villa MR, Ruiz-Valdepeñas AM, Lendinez C, Romero A, Franco F, Calvo V, Alfaro C, Acosta PM, Salas C, Garcia JM, Provencio M. Cruz-Bermúdez A, et al. Free Radic Biol Med. 2019 May 1;135:167-181. doi: 10.1016/j.freeradbiomed.2019.03.009. Epub 2019 Mar 14. Free Radic Biol Med. 2019. PMID: 30880247 Free article.
Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M, Pérez-Barrios C, Barquin M, Calvo V, Franco F, Sánchez E, Sánchez R, Marsden D, Cristóbal Sánchez J, Martin Acosta P, Laza-Briviesca R, Cruz-Bermúdez A, Romero A. Provencio M, et al. Clin Chem Lab Med. 2020 Jan 28;58(2):306-313. doi: 10.1515/cclm-2019-0745. Clin Chem Lab Med. 2020. PMID: 31469650
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
Romero A, Serna-Blasco R, Alfaro C, Sánchez-Herrero E, Barquín M, Turpin MC, Chico S, Sanz-Moreno S, Rodrigez-Festa A, Laza-Briviesca R, Cruz-Bermudez A, Calvo V, Royuela A, Provencio M. Romero A, et al. Transl Lung Cancer Res. 2020 Jun;9(3):532-540. doi: 10.21037/tlcr.2020.04.01. Transl Lung Cancer Res. 2020. PMID: 32676317 Free PMC article.
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Salas Antón C, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermúdez A. Provencio M, et al. Lancet Oncol. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. Epub 2020 Sep 24. Lancet Oncol. 2020. PMID: 32979984 Clinical Trial.
31 results